培美替尼(pemigatinib)治疗胆管癌的效果及不良反应

Pemetinib is a selective fibroblast growth factor receptor (FGFR) kinase oral inhibitor indicated for the treatment of patients with unresectable locally advanced or metastatic cholangiocarcinoma who have refractory or relapsed disease after receiving at least one systemic therapy and have FGFR2 fusions. So, what are the effects and adverse reactions of (pemigatinib) in treating cholangiocarcinoma?

The successive approvals of pemigatinib are based on the FIGHT-202 clinical study, which mainly evaluates the efficacy and safety of pemigatinib. Trial result data: Among patients carrying FGFR2 fusions or rearrangements, with a median follow-up of 15 months, the overall response rate (ORR) of pemetinib treatment was 36%, the median duration of response (DoR) was 7.49 months, and the disease control rate was 88.2%. The other two groups of patients who did not carry FGFR2 gene fusion or rearrangement had no obvious effect. It can be seen that pemetinib is mainly targeted at patients with cholangiocarcinoma containing FGFR2 gene fusion or rearrangement, and has good efficacy.

Adverse reactions: 58.2% of patients in the above studies experienced hyperphosphatemia, and ≥30% of patients experienced other adverse reactions such as hair loss, diarrhea, fatigue, difficulty stuttering, nausea, constipation, stomatitis, dry mouth and other adverse reactions. The above adverse reactions were all mild and controllable. In addition, ≥10% of patients experienced grade ≥3 adverse reactions, hypophosphatemia.

In 2018, Innovent Biologics and Incyte have reached a strategic cooperation and exclusive licensing agreement to promote the clinical development and launch of pemigatinib in mainland China, Hong Kong, Macau and Taiwan. Currently, Innovent is conducting clinical research in China on pemetinib for the treatment of patients with cholangiocarcinoma with FGFR2 gene fusion or rearrangement.

Note: The above information comes from the Internet and is compiled and edited by Medical Companion Travel (please correct me if there are any errors or omissions). It is only to provide information on the latest drugs on the market in the world and help Chinese patients understand the latest international new drug trends. It is only for internal discussion among medical staff and does not serve as any basis for medication. For specific medication guidelines, please consult the attending physician.